Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolonged Low-dose Decitabine + Venetoclax in Elderly AML/MDS
NCT06046313Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine, venetoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Started Oct 2023; status: recruiting.
02
Drugs
decitabinevenetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06046313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06046313.